Orano: Sanofi & Orano join forces to accelerate the development of develop nextgeneration radioligand medicines

Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development of targeted alphatherapies in oncology, have entered into an agreement to combine their expertise in the fight against rare cancers and further accelerate the development of next─generation radioligand medicines.